ALQAEM International, an exclusive master distributor of Biosign Technologies in the Middle East and North Africa Region (MENA), has placed an initial order of 2000 Biosign UFIT Ten-20 devices.
The initial order is required to meet greater than expected demand in several countries in the MENA region for Biosign’s Health Monitoring Solution and ALQAEM’s successful closing of its first Egyptian reseller.
As per the terms of the exclusive master distribution agreement, ALQAEM is expected to order in excess of 14,000 units by the end of 2011.
UFIT TEN-20 is an online medical device for self-monitoring of blood pressure and blood glucose. Biosign said that the device takes the pulse at the wrist through an inflatable cuff and immediately produces blood pressure and blood glucose measurement results.
The results are stored on Biosign servers along with the test sample and readings can be viewed by care providers on a secure web portal and/or integrated into a patient’s Electronic Health Record.
Biosign claimed that the UFIT TEN-20 is approved under ISO 13485 for the non-invasive measurement of blood pressure and blood glucose, and carries the CE mark.
ALQAEM managing director John Rizvi said that in August this year, the Saudi government announced $6bn is budgeted for eHealth spending in 2010 alone to help take on this challenge.
“We anticipate an enthusiastic response to the Biosign UFIT non-invasive solution in all MENA countries,” Rizvi said.